JOE Society for Endocrinology Archive
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Journal of Endocrinology (2002) 172, 615-625       DOI: 10.1677/joe.0.1720615
© 2002 Society for Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Soden, J
Right arrow Articles by Ray, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Soden, J
Right arrow Articles by Ray, D.
Journal of Endocrinology, Vol 172, Issue 3, 615-625
Copyright © 2002 by Society for Endocrinology


Articles

Genetic engineering of the glucocorticoid receptor by fusion with the herpes viral protein VP22 causes selective loss of transactivation

J Soden, A Stevens, and DW Ray


The development of methods for engineering proteins with novel properties opens the way to manipulating intracellular processes in a therapeutically useful way. Glucocorticoids, acting via glucocorticoid receptors (GR), are potent anti-inflammatory agents, acting to oppose nuclear factor kappa B (NF kappa B) function. The herpes viral protein, VP22, has been reported to confer intercellular trafficking activity on 'cargo' proteins, potentially facilitating gene therapy with intracellular proteins. VP22GR, resulting from the addition of VP22 to the N terminal of GR, was equipotent with the wild-type GR in opposing NF kappa B p65-driven expression of an NF kappa B reporter gene. Surprisingly, VP22GR was incapable of inducing transactivation of positive glucocorticoid reporter genes (MMTV-luc and TAT3-luc). Furthermore, the VP22GR had powerful dominant negative activity on both endogenous and exogenous GR transactivation. VP22GR was cytoplasmic in quiescent cells, and after hormone addition underwent nuclear translocation to share the same distribution as the GR. The ability of the VP22GR to selectively confer and enhance glucocorticoid-dependent transrepression of NF kappa B may be of use therapeutically in e.g. transplant rejection, inflammatory arthritis or asthma.


This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. Kayahara, J. Ohanian, V. Ohanian, A. Berry, R. Vadlamudi, and D. W. Ray
MNAR functionally interacts with both NH2- and COOH-terminal GR domains to modulate transactivation
Am J Physiol Endocrinol Metab, November 1, 2008; 295(5): E1047 - E1055.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
Z Alourfi, R P Donn, A Stevens, A Berry, A McMaster, and D W Ray
Glucocorticoids suppress macrophage migration inhibitory factor (MIF) expression in a cell-type-specific manner
J. Mol. Endocrinol., April 1, 2005; 34(2): 583 - 595.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
C E Waters, A Stevens, A White, and D W Ray
Analysis of co-factor function in a glucocorticoid-resistant small cell carcinoma cell line
J. Endocrinol., November 1, 2004; 183(2): 375 - 383.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the Society for Endocrinology.